NasdaqGM - Nasdaq Real Time Price ? USD Verona Pharma plc (VRNA) Follow Compare 38.81 +0.95 (+2.51%) At close: November 22 at 4:00 PM EST 38.00 -0.81 (-2.09%) After hours: November 22 at 6:01 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Verona Pharma Announces December 2024 Investor Conference Participation LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in December 2024: Piper Sandler 36th Annual Healthcare ConferenceDate: Tuesday, December 3, 2024Time: 12:00 p.m. ET / 5:00 p.m. GMTLocation: New York, NY 7th Annual Evercore HealthCONx ConferenceDate: Wednesday, December 4, 2024Time: 3:00 p.m. ET / 8:00 p.m. GMTLocation: Miami, GlobeNewswire ? 3 days ago VRNA +2.51% Verona Pharma (NASDAQ:VRNA) shareholder returns have been incredible, earning 724% in 5 years For many, the main point of investing in the stock market is to achieve spectacular returns. While not every stock... Simply Wall St. ? 17 days ago VRNA +2.51% Verona Pharma PLC (VRNA) Q3 2024 Earnings Call Highlights: Strong Ohtuvayre Launch Amid Rising Costs Verona Pharma PLC (VRNA) reports significant sales growth for Ohtuvayre, but faces increased expenses and competition in the COPD market. GuruFocus.com ? 17 days ago VRNA +2.51% Verona Pharma to Present at Jefferies London Healthcare Conference LONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 6:30 a.m. ET / 11:30 a.m. GMT. A webcast of the event will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com. For further information please contact: Verona P GlobeNewswire ? 17 days ago VRNA +2.51% Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update Ohtuvayre? (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more than 2,200 unique prescribers and more than 5,000 prescriptions filled across a broad COPD population Pipeline expansion continues: Phase 2 programs enrolling Conference call today at 9:00 a.m. ET / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focu GlobeNewswire ? 18 days ago VRNA +2.51% Recent Price Trend in Verona Pharma (VRNA) is Your Friend, Here's Why Verona Pharma (VRNA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. Zacks ? 28 days ago VRNA +2.51% Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma have been highlighted in this Industry Outlook article. Zacks ? 28 days ago VRNA +2.51% EXEL BPMC 5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, BPMC, CRSP, FOLD and VRNA well in this volatile sector. Zacks ? 29 days ago EXEL VRNA +2.51% ^GSPC Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update LONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the third quarter ended September 30, 2024 on Monday, November 4, 2024 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. GMT to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: GlobeNewswire ? last month VRNA +2.51% Wall Street Analysts Think Verona Pharma (VRNA) Could Surge 25.25%: Read This Before Placing a Bet The average of price targets set by Wall Street analysts indicates a potential upside of 25.3% in Verona Pharma (VRNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. Zacks ? last month VRNA +2.51% Verona Pharma (VRNA) Is a Great Choice for 'Trend' Investors, Here's Why Verona Pharma (VRNA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen. Zacks ? last month VRNA +2.51% Verona Pharma to Present Six Analyses of the?Phase 3 ENHANCE Studies in COPD at CHEST 2024 Data support Ohtuvayre? (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 in a broad COPD populationLONDON and RALEIGH, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces four oral presentations and two posters on analyses from its successful Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease (“COPD”) will be presented at CHEST Annual Mee GlobeNewswire ? last month VRNA +2.51% Insider Sale: CFO Mark Hahn Sells 600,000 Shares of Verona Pharma PLC (VRNA) On September 11, 2024, Mark Hahn, the Chief Financial Officer of Verona Pharma PLC (NASDAQ:VRNA), executed a significant transaction by selling 600,000 shares of the company. The sale was documented in a recent SEC Filing. Following this transaction, the insider now owns 14,339,688 shares of Verona Pharma PLC. GuruFocus.com ? 2 months ago VRNA +2.51% Verona Pharma PLC (VRNA) CEO David Zaccardelli Sells 600,000 Shares The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 15,250,704 shares of Verona Pharma PLC. Verona Pharma PLC is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for respiratory diseases. GuruFocus.com ? 2 months ago VRNA +2.51% Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024 One oral presentation and three posters support Ohtuvayre? (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces one oral presentation and 3 posters on additional analyses from its successful Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease (“COPD”) will be presented at GlobeNewswire ? 2 months ago VRNA +2.51% Insider Sale: CFO Mark Hahn Sells 400,000 Shares of Verona Pharma PLC (VRNA) Mark Hahn, the Chief Financial Officer of Verona Pharma PLC (NASDAQ:VRNA), executed a significant transaction on August 13, 2024, where the insider sold 400,000 shares of the company. Following this transaction, the insider now owns 14,939,688 shares of Verona Pharma PLC. Verona Pharma PLC is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases. GuruFocus.com ? 3 months ago VRNA +2.51% Is Verona Pharma plc (VRNA) a Good Addition to Your Portfolio Now? We recently compiled a list of the Top 10 Holdings of Caligan Partners. In this article, we are going to take a look at where Verona Pharma plc (NASDAQ:VRNA) stands against Caligan Partners’ other top holdings. Founded in 2017, Caligan Partners is one of the most significant specialty hedge funds. David Johnson is the brainchild behind […] Insider Monkey ? 3 months ago VRNA +2.51% ^GSPC Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update OhtuvayreTM (ensifentrine) now available; patient shipments started Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the second quarter ended June 30, 2024, and provides a corporate update. “We are GlobeNewswire ? 3 months ago VRNA +2.51% Verona Pharma plc's (NASDAQ:VRNA) Path To Profitability With the business potentially at an important milestone, we thought we'd take a closer look at Verona Pharma plc's... Simply Wall St. ? 3 months ago VRNA +2.51% Verona Pharma to Present at 44th Annual Canaccord Growth Conference LONDON and RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the 44th Annual Canaccord Growth Conference on Tuesday, August 13, 2024, at 1:30 p.m. EDT / 6:30 p.m. BST. A webcast of the event will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com. For further information please contact: Verona Ph GlobeNewswire ? 3 months ago VRNA +2.51% Performance Overview Trailing total returns as of 11/23/2024, which may include dividends or other distributions. Benchmark is MSCI WORLD Return VRNA MSCI WORLD YTD +95.22% +18.83% 1-Year +176.23% +25.33% 3-Year +680.89% +17.63%
